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Abstract The use of robot-assisted surgery (RAS) has gained
popularity in the field of gynaecology, including pelvic floor
surgery. To assess the benefits of RAS, we conducted a sys-
tematic review of randomized controlled trials comparing lap-
aroscopic and robotic-assisted sacrocolpopexy. The Cochrane
Library (1970–January 2015), MEDLINE (1966 to January
2015), and EMBASE (1974 to January 2015) were searched,
as well as ClinicalTrials.gov and the International Clinical
Trials Registry Platform. We identified two randomized trials
(n=78) comparing laparoscopic with robotic sacrocolpopexy.
The Paraiso 2011 study showed that laparoscopic was faster
than robotic sacrocolpopexy (199 ± 46 vs. 265 ± 50 min;
p< .001), yet in the ACCESS trial, no difference was present
(225±62.3 vs. 246.5±51.3 min; p= .110). Costs for using the
robot were significantly higher in both studies, however, in the
ACCESS trial, only when purchase and maintenance of the
robot was included (LSC US$11,573 ± 3191 vs. RASC
US$19,616 ± 3135; p< .001). In the Paraiso study, RASC
was more expensive even without considering those costs
(LSC US$ 14,342 ± 2941 vs. RASC 16,278 ± 3326;
p=0.008). Pain was reportedly higher after RASC, although
at different time points after the operation. There were no
differences in anatomical outcomes, pelvic floor function,
and quality of life. The experience with RASC was tenfold
lower than that with LSC in both studies. The heterogeneity
between the two studies precluded a meta-analysis. Based on
small randomized studies, with surgeons less experienced in
RAS than in laparoscopic surgery, robotic surgery significant-
ly increases the cost of a laparoscopic sacrocolpopexy. RASC
would bemore sustainable if its costs would be lower. Though
RASCmay have other benefits, such as reduction of the learn-
ing curve and increased ergonomics or dexterity, these remain
to be demonstrated.
Keywords Sacrocolpopexy . Laparoscopy . Pelvic organ
prolapse . Vault prolapse . Robotics . Costs
Introduction
Robotic-assisted surgery
Robot-assisted surgery (RAS) has become popular in various
surgical fields, including gynaecology and urology. Accord-
ingly, the robot has been used for the surgical treatment of
pelvic organ prolapse (POP). The most frequently quoted ad-
vantages of RAS are its 3D view, the elimination of surgeon
tremor whilst permitting precise and intuitive movements.
Further to this the use of wristed instruments improves
Electronic supplementary material The online version of this article
(doi:10.1007/s10397-016-0930-z) contains supplementary material,
which is available to authorized users.
* Jan Deprest
jan.deprest@uzleuven.be
1 Department of Development and Regeneration, Cluster Organ
Systems, Faculty of Medicine, Group Biomedical Sciences, KU
Leuven, 3000 Leuven, Belgium
2 Department of Obstetrics and Gynaecology, University Hospitals
Leuven, 3000 Leuven, Belgium
3 Belgian Center for Evidence Based Medicine (CEBAM), Belgian
Branch of the Cochrane Collaboration, 3000 Leuven, Belgium
4 Department of Obstetrics and Gynaecology, Jessa Hospital,
3500 Hasselt, Belgium
5 Department of Urology, University Hospitals Leuven,
Leuven, Belgium
6 Department of Gynaecologic Oncology, Leuven Cancer Institute,
University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium
Gynecol Surg (2016) 13:115–123
DOI 10.1007/s10397-016-0930-z
dexterity offering more favorable ergonomics. RAS combines
these advantages with the minimally invasive approach,
i.e., those already demonstrated for conventional or
Bstraight stick^ laparoscopy. Wide introduction of RAS
is mainly limited by the high acquisition and maintenance
cost (usually around 10 % of the purchase cost per year)
and the repetitive costs of the consumables [1]. In Europe,
the initial cost is typically depreciated over 7 or more
years, which amounts to more than 1000 € per patient,
when used for 300 or more procedures per year [2]. When
used in fewer patients, this will result in higher per-case
charges. The use of robotic instruments is limited to 10
cases, and the list charge price for three instruments is
easily more than 1500 € [3]. Next to the high costs, other
disadvantages are the lack of tactile feedback and instru-
ment crowding, especially in a narrow operating field,
such as the pelvis [2].
Minimally invasive pelvic floor surgery
Whereas most patients with symptomatic POP can be ade-
quately managed by the vaginal route, correction of apical
descent or multi-compartment prolapse with a so-called level
I defect is better treated by the abdominal approach [4]. In
sacrocolpopexy (SC), the vaginal vault and/or cervix is fixed
by means of a graft to the anterior longitudinal ligament over
the sacrum. Sacrocolpopexy by laparotomy further referred to
as abdominal sacrocolpopexy (ASC) yields an over 90 % suc-
cess rate, which improves on sacrospinous fixation. This is
however at the expense of longer operation times, higher mor-
bidity, and increased hospital cost [4]. These shortcomings are
avoided by performing SC by minimal access, either by lapa-
roscopy (LSC) or by its robotic-assisted equivalent (RASC).
Despite the lower performance of spinofixation, single inci-
sion vaginal mesh prolapse repair seemed to be a reasonable
alternative to LSC, as it was supposed to combine the dura-
bility and comprehensiveness of a mesh repair and the advan-
tages of the vaginal route. In Maher’s randomized clinical trial
(RCT), LSCwas associated with a shorter hospital stay, earlier
return to daily activity, better 2-year anatomical outcomes, less
graft related complications, and, as a consequence, less
reinterventions as well as lower hospital costs, despite longer
operation times [5, 6].
Only by 2012, level I evidence became available
supporting the hypothesis that a laparoscopic SC yields as
good anatomic (point C) and subjective (patient global im-
pression score) outcomes as the same operation by laparotomy
[7]. Moreover, LSC was associated with less blood loss, less
pain, and a shorter hospital stay. Conversely, operation time,
return to normal activities, or functional effects were similar
for both modalities.
LSC unfortunately did not become widely implemented,
because of its steep learning curve and long operation times,
adding to the generic disadvantages of a limited number of
degrees of freedom and its two-dimensional vision [8]. These
disadvantages could be circumvented by robotic assistance.
The da Vinci Surgical System® (Intuitive Surgical Inc., Sun-
nyvale, CA, USA) is at present the only operational and com-
mercially available surgical robot. Its increased magnification,
three-dimensional vision, physiologic tremor filtering, and 7
degrees of freedom are believed to provide the surgeon with
an enhanced ergonomic environment, simplifying complex
laparoscopic tasks such as suturing and knot tying, which
are essential techniques for SC. The implementation of robots
was surprisingly quick into the clinical practice of
gynaecologists in many Western countries. This may be by a
combination of extensive marketing but certainly because
RAS answers the needs of some robotic surgeons not familiar
with conventional laparoscopic surgery. Subsequently, there
has been a significant body of reassuring studies on RASCP
demonstrating safety and efficacy, reviewed by Serati et al. [9].
Though there is to our knowledge no RCT comparing RASCP
to ASCP, it seems that anatomical and functional outcomes are
comparable, though with reduced morbidity, which logically
would be the consequence of the minimal access route.
This experience has led to statements that RAS is Bbetter
than conventional surgery^—which is clearly stated on the
manufacturer’s website [10]. The latter is misleading at least,
because today conventional sacrocolpopexy no longer is the
synonym of ASC [10]. Given the level I evidence that LSC
overall is better than ASC, the laparoscopic approach should
theoretically be the standard and point of reference. Herein,
we aimed to investigate whether there is at present any evi-
dence that RASC would by any outcome measure be superior
to LSC. Acceptable advantages would be respectively, a clin-
ical benefit to the patient, a reduced health care cost, or im-
proved surgeon’s ergonomics. This question is timely: with
the aging and increasing activity of the population, the de-
mand for prolapse surgery is only expected to increase. Given
the movement away from vaginal mesh use, minimal access




Relevant studies were identified from the Cochrane Library
(1970–January 2015), MEDLINE (1966 to January 2015),
and EMBASE (1974 to January 2015). Furthermore,
ClinicalTrials.gov and the International Clinical Trials Regis-
try Platformwere searched for ongoing and completed clinical
trials. Language restrictions were not applied. There was no
systematic attempt to search the grey literature. Details of the
search strategy can be found as an online resource. Essentially,
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RCTs or controlled studies were included if they compared
laparoscopic (LASC) with robotic-assisted sacrocolpopexy
(RASC) as the primary surgical intervention with or without
concomitant surgery.
Data collection and analysis
All titles and abstracts retrieved by electronic searching were
independently assessed by two review authors (GC and JB).
Studies that did not meet the inclusion criteria were excluded,
and full-text copies of the potential eligible studies were ob-
tained. The full-text articles were assessed for eligibility inde-
pendently. Disagreements were resolved through discussion
or arbitration by a third review author (JD).
For data extraction, a standard form available from the
website of the Cochrane Library was used (data collection
form for intervention reviews: RCTs only, version 3, April
2014). Two review authors (JB, GC) extracted data from eli-
gible studies. When studies included data from multiple pub-
lications, the main trial report was used, supplemented by a
previous published protocol if available. Differences were re-
solved through discussion or arbitration by a third review
author (JD).
Primary outcomes were the use of resources and costs (in-
cluding equipment/theatre costs, length of hospital stay in
days, duration of operation in minutes, number of outpatient
attendances, number of days off work, direct medical resource
use, direct medical costs. Secondary outcomes were patient
satisfaction parameters, measured by any validated question-
naire (e.g., PGI-I, PGIC, POP-specific quality of life
(P-QoL)); objective measurement of cure rate (POP-Q stage);
any complication, either intraoperative, postoperative within
6 weeks, or at a later stage during follow-up, and its nature;
early mortality (death within 30 days); estimated blood loss;
rate of conversion to open surgery (for RAS versus CLS) and
the reason for conversion; and postoperative pain (VAS or
other validated scale).
The selected studies were assessed for methodological
quality using the Brisk of bias^ tool of the Cochrane Collabo-
ration [11]. The method of randomization, allocation conceal-
ment, blinding, loss to follow-up, selective outcome reporting,
trial funding, and if present other sources of bias were again
independently evaluated arbitrated as above.
Statistical analysis
For the main outcome of interest, Buse of resources and costs,^
the mean values, and the standard deviations (SD) were ex-
tracted. For the other outcomes, if binary, the number of
events was noted. Since the number of RCTs was limited
and the used definitions of essential outcome measures were
different, additional meta-analysis was not performed.
Results
A flow diagram of the search process is displayed in Fig. 1.
The search yielded 272 citations of which 24 underwent full
text review after screening of the titles and abstracts. Twelve
manuscripts concerning the two same studies were included in
the SR after consideration of the full text. Both studies were
RCTs comparing laparoscopic to robotic sacrocolpopexy of
similar size (n=78; Anger 2014 and Paraiso 2011); the former
had hospital cost as a primary outcome measure, whereas in
the latter it was operation time. Both studies reported both
variables. The characteristics of these studies are summarized
in Table 1; the outcomes in Table 2. Required surgeon’s ex-
perience with RASC prior to the study was similar: surgeons
Fig 1 Study flow diagram
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were to have performed at least 10 prior robotic procedures.
The actual performance was not mentioned in either report.
Sacrocolpopexy was performed using two separate pieces of
polypropylene mesh. Concomitant procedures were allowed
and equally distributed between the two arms in both studies,
including retropubic mid-urethral sling and anterior or poste-
rior repairs. Of note is that in Anger’s ACCESS trial, 58 % of
women underwent a concomitant hysterectomy, whereas in
the study by Paraiso only patients with posthysterectomy vault
prolapse were included. Other differences at baseline were the
setup (single versus two centers) and indication (vault pro-
lapse and/or uterine descent).
The studies also had comparable secondary outcomes
which were limited to surgical complications and blood loss,
postoperative pain, objective cure rate, and patient satisfac-
tion. Both studies used a blinded computer-based
Table 1 Study characteristics
Study Paraiso 2011 Anger 2014
Design Parallel-group, single-center trial RCT Two-center, parallel-group RCT
Ethical approval Yes Yes
Power calculation Yes—to detect a 50-min difference in
operating time with 90 % power and
5 % type 1 error
Yes—to detect at least US$2500 difference in total
charges with 95 % power and 5 % type 1 error
CONSORT statement Yes No
Conflict of interest No conflicts of interest No conflicts of interest
Participants Country: USA
Setting: Cleveland Clinic
Population: women >21 years presenting with
posthysterectomy vaginal apex prolapse with POP-Q
stage 2–4 desiring surgical management between
January 2007 to December 2009
Patients were excluded if not candidates for general
anesthesia, underwent a prior sacral colpopexy or
rectopexy, had a history of PID, had a BMI >40 kg/m2
Country: USA
Setting: University of California-Los Angeles/Cedars-
Sinai and Loyola University Medical Centers
Population: women with symptomatic pelvic organ
prolapse stage II or greater and clinical indication for
sacrocolpopexy
Patients were excluded if future childbearing, pregnant
or pregnancy in the last 12 months, unable to read,
write, and comprehend English
Interventions Sacrocolpopexy using 2 separate 4 × 15 cm pieces of
polypropylene mesh. Use of 4 ports for the
laparoscopy, 5 for the robotic-assisted laparoscopy
in W formation
Sacrocolpopexy with 2 separate pieces of
polypropylene mesh and Gore-Tex sutures—
surgeon’s preference determined brand of the mesh
and closure of the retroperitoneal lining
Randomization method Computer-generated randomization schedule—stratified
by surgeon
Computer-based block randomization based on site and
need for concurrent hysterectomy randomization on
the day of the surgery
Allocation concealment Use of opaque envelopes Treatment allocation is uploaded on a password
protected website—randomization assignment is
revealed to treating surgeon on the day of surgery
Under procedure in patient file: laparoscopic
sacrocolpopexy per the ACCESS protocol
Blinding Blinding of research staff and patients Blinding of patients and research staff for 6 weeks
after surgery
Groups comparable Yes Yes
Intention-to-treat analysis Yes Yes
Follow-up Up to 1 year Up to 1 year
Loss to follow-up 4 lost to FU after surgery from LASC
2 from RASC
3/78 before 6 M FU visit
Intervention group Robotic-assisted sacrocolpopexy (randomized:
n= 40—underwent surgery n= 35)
RASC (n= 40)
Control group Laparoscopic sacrocolpopexy (randomized:
n= 38—underwent surgery: n = 33)
LASC (n = 38)
Concomitant surgery Yes Yes
Surgical experience At least 10 robotic procedures At least 10 procedures of each type
Outcome measures Primary outcome: operating time
Secondary outcomes: postoperative pain, use of
NSAIDs, complications, costs, postoperative
subjective and objective cure rate
Primary outcome: costs
Secondary outcomes: surgical outcomes (blood loss
and postoperative pain), POP-Q, symptom severity
and QoL, adverse events
118 Gynecol Surg (2016) 13:115–123
randomization system, hence having low risk for selection
bias. Both assessors and patients were blinded to treatment
allocation. The data were analyzed on an intention-to-treat
basis. In the study by Paraiso, 13 % of the study population
(n=10) was lost after randomization and prior to surgery.
Surprisingly, four patients were excluded because they did
not meet the criteria, and six others because of patient choice
or illness, so attrition bias was considered unclear. Conversely,
the attrition bias of the ACCESS trial was low: there were five
patients lost to follow-up after the surgery, equally distributed
over both treatment arms. The summary of the risk of bias
assessment can be found in Fig. 2. Reporting bias is low for
both studies; both protocols were also published upfront [12,
13]. Remarkably, the published protocol of the ACCESS trial
mentioned initially a follow-up of 1 year postoperatively, yet
in the publication a 6-month follow-up is reported on.
Both studies came to different conclusions in terms of the
measures initially put forward as primary outcome by either
group. In the hands of Paraiso et al., LSC was faster than
RASC (199±46 vs. 265±50 min; p< .001), yet Anger et al.
did not find a difference (225± 62.3 vs. 246.5 ± 51.3 min;
p= .110). Both trials report a significantly higher cost for
RASC, yet they use different definitions. The ACCESS breaks
down the healthcare costs as those made by the health care
provider, first related to the initial procedure, and secondly
those related to potential readmissions within 6 weeks. For
the surgery-related cost, they report both the purchase of the
robot and the maintenance cost as well as its consumables.
Eventually, the higher costs in the ACCESS trial (LSC
US$11,573± 3191 vs. RASC US$19,616± 3135; p< .001)
were only due to the higher purchase and maintenance cost
of the robot. Excluding those costs, the healthcare cost was
actually comparable, with or without concomitant surgery
(LSC US$11,573±3,191 vs. 12,586±3315; p= .160) [14].
This is different for the other study. Firstly, Paraiso does not
consider the purchase and maintenance cost of the robot. Even
when leaving this contributor to costs, they still find signifi-
cant higher costs for the RASC (LSC US$14,342±2941 vs.
Table 2 Outcomes
Outcome Paraiso 2011 Anger 2014
LSC (n= 33) RASC (n= 35) Mean difference P LSC (n= 38) RASC (n = 40) P
Time—sacrocolpopexy 162 ± 47 min 227 ± 47 min 67 (CI 43–89) <.001 178.4 ± 49.8 min 202.8 ± 46.1 min .030
Time—total operation operating 199 ± 46 min 265 ± 50 min 66 (43–90) <.001 225.5 ± 62.3 min 246.5 ± 51.3 min .110
Costs
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LSC laparoscopic sacrocolpopexy, RASC robotic-assisted sacrocolpopexy, NSAIDs nonsteroidal anti-inflammatory drugs, VAS visual analog scale, no
data available, Excluding robotics excluding costs of purchase and maintenance costs for robot
a Only visual scale (no raw data)
Fig 2 Risk of bias summary: review authors’ judgements about each risk
of bias item for each included study
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RASC 16,278±3326; p=0.008). That difference was primar-
ily driven by the higher operating room cost for RASC, and
not the costs related to Bhospitalization^ [12].
In essence therefore, when using similar definitions of op-
erating cost, there were no differences in costs in one but not in
the other study. In a nutshell, the operational costs excluding
purchase and maintenance were comparable in the former
study, but not in the latter. When it comes to investments,
purchase costs were not included in one study [12], though
were higher when taken into account. The magnitude is as
given above, though it is worth noting that the costs of the
laparoscopic equipment was not computed by Anger et al.,
therefore the difference may be exaggerated.
Clinical outcomes were also reported with no difference in
complications. In Paraiso et al., three conversions were reported,
all in the robotic arm, one to laparotomy, two to LSC. In Anger
et al., there were no conversions. Both studies report higher
postoperative pain for RASC patients. This persists for only
the first week following surgery in the Anger cohort and bet-
ween three and five weeks for Paraiso, though the scales used
were again not comparable. However supporting this observa-
tion in Paraiso's study was the extended use of painkillers fol-
lowing RASC (11 days versus 20 days; p< .005) [12]. This was
not reported by Anger. Efficacy (anatomical outcome) of the
procedure was equivalent on short term (6 months [14] or 1 year
[12]). The pelvic floor dysfunction and quality of life question-
naires partially overlapped for both studies, yet there were no
differences observed again at slightly different time points.
Because of the differences in definitions of essential
(primary) outcome measures, we decided not to pool the re-
sults for a formal meta-analysis.
Discussion
RASC may be equally effective yet is more expensive
Though efficacy was not a primary outcome in this study, it is
reasonable to assume that RASC and LSC are equally effica-
cious. In reality, it may numerically be very difficult to design a
study that would show the opposite. The available randomized
trials logically looked at other aspects; one of these being costs.
When taking into account the purchase and maintenance costs,
the ACCESS trial demonstrates an increased cost when the
robot is used [14]. Although the costs of consumables were
only reported in one study [12], they are higher than for straight
stick LSC. The above is in line with earlier observational stud-
ies on the same procedure [15, 16]. Given that hardware and
consumable costs are among the principal cost drivers, another
result would have been surprising. Other firm contributors are
typically operation time and hospital stay, yet they are compa-
rable in one RCT [14] and several observational studies [17,
18] and hence cannot compensate for the increased Bmaterial^
costs. This is also in line with randomized studies on other
procedures, such as hysterectomy [19], fundoplication [20],
and right hemicolectomy [21], as well as the numerous obser-
vational studies [22–25]. Obviously, one cannot compare all
these studies of different design and quality, and it seems that,
roughly spoken, one looks at an excess cost of US$2–3000 [26,
27]. Whether one would come to the same magnitude of excess
costs in a European setting or elsewhere remains to be studied,
yet, proportionally spoken, it is unlikely that there is a cost
model where this difference would not show.
Both studies consistently report more short-term pain,
though at later timepoints it is difficult to compare outcomes
as different measurement methods were used. This aspect has
not been very well studied in observational studies on SC,
with one study showing similar levels of postoperative pain
[17] or (randomized) studies on other procedures. Park et al.
found no significant difference in postoperative pain in a RCT
comparing robotic and laparoscopic right hemicolectomy in
cancer patients [21]. It is therefore difficult to draw a firm
conclusion, though the clinical relevance of increased pain
sensation over a very short time with limited increase in pain
relief is probably not very important. Further research into the
actual cause of a difference in painmay demonstrate the blame
does not lay with the robot. For instance, it has been speculat-
ed that this may be due to an increased diameter and/or in-
creased tension on the robotic ports, which theoretically can
be remediated by further technologic advancements.
The question is how solid one considers the evidence for
the above conclusions. First, there are the methodological dif-
ferences on definition of costs, pain, etc. This is inherent when
there are no gold standard methods for this type of research.
The two available studies may however be individually criti-
cized as well. One can argue what is the most relevant end-
point to study, but it seems completely acceptable to us to take
cost as a relevant outcome measure in the current economic
situation.Whether the choice for a hospital cost analysis rather
than a cost study that looks further than that, is right, may be
another point of discussion. It seems however fair to us for a
hospital to first do a cost-minimization study as management
decisions will be primarily based on the outcomes of such
study. Operation time is also an acceptable endpoint as this
proxy for surgical efficiency bears relevance both to surgeons
as well as hospital management. From amethodological view-
point, it could be argued that it is uncertain whether the surgi-
cal skills and experience at the onset of the RCTwere compa-
rable for both treatment modalities. Both studies state that a
minimum of 10 RASC was required, though actual numbers
are lacking. We requested that information, and both authors
kindly provided their best estimate, ranging between 10 and15
for two surgeons and 50 for two other surgeons for the study
by Anger et al. For the study by Paraiso et al., one surgeon had
a previous experience of 400–500 LSCs and 10 RASCs and
the other surgeon had performed about 100 LSCs and 10
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RASCs. Nevertheless, even under the Bbest^ circumstances of
a very experienced team, it seems not possible to overcome
the limitation of an increased cost.
In summary, these two RCTs are the best available evi-
dence and consistently demonstrate higher costs without mea-
surable benefit to the patient. We therefore agree with Steege
and Einarsson [10] that stating Brobotic is better than conven-
tional surgery^ is not supported by high-quality evidence at
present. In the absence of any evidence of superiority, is the
Bproblem of how to implement the technology … moot^, as
the Editorial suggests [10]?
Speculations on future place of robotic in pelvic floor
surgery
Nonetheless, this does not mean the robot does not have some
assets. Laparoscopic surgeons frequently report discomfort in
the neck and upper extremities as well as experience higher
stress levels [28–30]. A more static posture during LSC as
opposed to open surgery is blamed for this adverse effect
[31]. For relatively lengthy operations such as SC
(sacrocolpopexy), this may not be a trivial observation. Re-
gardless, this adds to the inherent limited degree of freedom of
motion by Bstraight stick^ laparoscopic instruments, which
impacts female surgeons more than male and surgeons with
smaller hands [30, 32]. Also, in some outdated operating the-
atres, the inappropriate positioning or limited numbers of
monitors may be disturbing [33, 34].
Previously, Tarr et al. studied the ergonomic impact specif-
ically for sacrocolpopexy in a prospective cohort of 33 RASC
and 53 LSC procedures over a 16-month period [35]. The
procedures were performed by a variety of surgeons at differ-
ent seniority (resident, fellow, attending), though all were pre-
viously trained with the studied modalities. As outcome mea-
sures, they used a validated five-step score for measuring
BBody Part Discomfort^ (BPD) in different body regions
and the National Aeronautics and Space Administration Task
Load Index (NASA-TLI), rating, e.g., mental and physical
demands, and effort and frustration with given tasks on a
continuous scale. [36]. In a nutshell, this study showed that
RASC was associated with lower neck, shoulder, and back
discomfort scores [35]. Stress levels, measured by skin con-
ductance level, and heart rate were significantly lower in sur-
gically inexperienced medical students performing tasks with
the robot when compared to laparoscopic instrumentation
[37]. These findings will need to be validated in a proper
RCT and a more homogenous population of surgeons.
Another view is that RASC in the hands of a novice, or of a
lesser experienced laparoscopist, is the most safe and effective
tool to perform advanced procedures [38]; hence, the econom-
ical disadvantages can be ignored. Assuming that one can
unequivocally demonstrate that RASC is much easier to be
learned than LSC (no study has shown this to our knowledge),
it may be, at a larger scale, the most pragmatic solution for the
long and demanding learning process typical for this proce-
dure [8, 39, 40]. Indeed, we have shown that 30 LSCs are
required to achieve an operation time within the range of an
experienced surgeon, and 60 procedures to obtain similar
complication rates [39]. This, combined with the relative
low numbers of sacrocolpopexies at each individual training
unit, makes adequate training problematic [8]. Robotics in a
setting with a double console could be safer and more effec-
tive to train junior surgeons. This is however far from certain:
one study demonstrated that robotic hysterectomy actually
had a longer learning curve (n=91) than what we described
for LSC [41]. From a training perspective, one could also
follow another strategy and try to shorten the learning process,
for instance, by a wider introduction of 3-D LSC [42]. This
may require an investment—which is probably less than for a
robot—yet will not have the repetitive instrument cost.
For us, there is no doubt that robotic developments boost
surgical capacities. Articulation beyond normal manipulation,
tremor reduction, and all the other claimed advantages may not
be proven; however, these properties, and the improved ergo-
nomics, are a true paradigm shift in surgery. For that alone, the
technology warrants further development. Certainly in the field
of urogynaecology, for some relatively complex procedures,
such as mesh removal, or more novel procedures such as those
for urge incontinence, which require bilateral extensive retro-
peritoneal dissections, there might be a benefit [43].
In conclusion, robotic surgery significantly adds to the
costs. To make it sustainable, and to allow further investments
in a technology which has not reached its limits, we must
move to a more reasonable cost. This can either result from
the arrival of a competitor (long expected but not yet a reality)
[2] or by negotiating a more reasonable and affordable price
either for the hospital [44] or at a higher level. The latter
approach has been successfully undertaken in Belgium
through negotiation with the medical drug industry [45].
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